A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma

被引：0
|
作者：
Young, Patricia A.
Mataveli, Fabio D.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137784
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
    Dholaria, Bhagirathbhai
    Mamuye, Admasu
    Yurewicz, Diana
    Dabovic, Kristina
    Yuet, Amy
    Abonour, Rafat
    Kelly, Kevin R.
    Voorhees, Timothy J.
    Kazandjian, Dickran
    BLOOD, 2022, 140 : 12621 - 12622
  • [2] A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TAK-169 in Patients With Relapsed or Refractory Multiple Myeloma
    Kumar, Shaji
    Mamuye, Admasu
    Dabovic, Kristina
    Wang, Jingyuan
    Roy, Vivek
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 : S10 - S11
  • [3] Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma.
    Lust, John Anthony
    Barranco, Charles
    Lacy, Martha
    Dispenzieri, Angela
    Gertz, Morie A.
    Dingli, David
    Russell, Stephen J.
    Buadi, Francis
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    Kumar, Shaji
    Usmani, Saad Zafar
    Thompson, John
    Taylor, Catherine
    Dondero, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma
    Rasco, Drew
    Tolcher, Anthony
    Siu, Lillian L.
    Heinhuis, Kimberley
    Postel-Vinay, Sophie
    Barbash, Olena
    Egger, Jacqueline L.
    Gorman, Shelby
    Horner, Thierry
    Dhar, Arindam
    Kremer, Brandon E.
    CANCER RESEARCH, 2017, 77
  • [5] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Ghamande, Sharad
    Lin, Chia-Chi
    Cho, Daniel C.
    Shapiro, Geoffrey I.
    Kwak, Eunice L.
    Silverman, Michael H.
    Tseng, Yunlong
    Kuo, Min-Wen
    Mach, Wendy B.
    Hsu, Shu-Chi
    Coleman, Teresa
    Yang, James Chih-Hsin
    Cheng, Ann-Lii
    Ghalib, Mohammad H.
    Chuadhary, Imran
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 445 - 451
  • [6] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Sharad Ghamande
    Chia-Chi Lin
    Daniel C. Cho
    Geoffrey I. Shapiro
    Eunice L. Kwak
    Michael H. Silverman
    Yunlong Tseng
    Min-Wen Kuo
    Wendy B. Mach
    Shu-Chi Hsu
    Teresa Coleman
    James Chih-Hsin Yang
    Ann-Lii Cheng
    Mohammad H. Ghalib
    Imran Chuadhary
    Sanjay Goel
    Investigational New Drugs, 2014, 32 : 445 - 451
  • [7] Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma
    Lust, John A.
    Usmani, Saad Z.
    Hamadani, Mehdi
    Barranco, Charles
    Lacy, Martha Q.
    Dispenzieri, Angela
    Gertz, Morie A.
    Dingli, David
    Russell, Stephen
    Buadi, Francis K.
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    Thompson, John
    Taylor, Catherine A.
    Dondero, Richard
    BLOOD, 2012, 120 (21)
  • [8] A study to evaluate the safety, tolerability, and pharmacokinetics of multiple weekly doses of intravenous dalbavancin in healthy subjects
    Dunne, Michael W.
    Sprenger, Craig
    Moriarty, Susan
    PHARMACOTHERAPY, 2013, 33 (10): : E261 - E261
  • [9] The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study
    Vose, Julie M.
    Friedberg, Jonathan W.
    Waller, Edmund K.
    Cheson, Bruce D.
    Juvvigunta, Vasthala
    Fritsch, Holger
    Petit, Claude
    Munzert, Gerd
    Younes, Anas
    LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 708 - 713
  • [10] An Open-Label, Sequential Dose-Escalation, Safety, and Tolerability Study of Rimabotulinumtoxinb in Subjects With Cervical Dystonia
    Chinnapongse, Robert
    Pappert, Eric J.
    Evatt, Marian
    Freeman, Alan
    Birmingham, William
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2010, 120 (11) : 703 - 710
12345